ProGnosis Biotech

ProGnosis Biotech

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.1M

Overview

ProGnosis Biotech is an EU-based diagnostics company founded in 2015, developing and manufacturing ELISA and Lateral Flow Tests for food safety, clinical diagnostics, and hygiene monitoring. The company leverages its antigen-antibody technology platform to deliver rapid, reliable, and eco-friendly testing solutions validated by international bodies. With ISO-certified production and a growing portfolio, ProGnosis serves global markets while expanding into new areas like cardiac markers and contract manufacturing services.

Infectious DiseaseCardiovascular

Technology Platform

Immunoassay platform specializing in the development and manufacturing of ELISA (Enzyme-Linked Immunosorbent Assay) and Lateral Flow Assays (LFAs) with a focus on eco-friendly innovations like non-organic solvent extractions.

Funding History

1
Total raised:$2.1M
Seed$2.1M

Opportunities

Expansion into the high-volume cardiac marker testing segment and growth of its contract manufacturing (CDMO) services for lateral flow assays present significant scalable opportunities.
Increasing global stringency in food safety regulations and the trend toward decentralized, rapid clinical testing drive sustained demand across its core markets.

Risk Factors

Intense competition from large global diagnostics firms and evolving regulatory landscapes (e.g., EU IVDR) pose significant market and compliance risks.
The company's reliance on the respiratory diagnostics market and complex supply chains for raw materials also introduces volatility and potential disruption risks.

Competitive Landscape

ProGnosis competes in fragmented but competitive markets against large multinational life science tools companies (e.g., Thermo Fisher, Merck) and specialized diagnostics firms (e.g., R-Biopharm, Hygiena). Its differentiation lies in its EU-based manufacturing, eco-innovative processes, multi-sector focus, and validation by recognized international bodies.